Taysha Gene Therapies TSHA 深 沪
等待开盘 07-22 09:30:00 美东时间
2.53
-0.040
-1.56%
华盛通- 最 高2.675
- 今 开2.59
- 成交量 272.40万股
- 最 低 2.47
- 昨 收 2.57
- 总市值 6.63亿
- 52周最高 3.31
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 1.05
- 委 比 -98.83%
- 总股本 2.62亿
- 历史最高 33.35
- 量 比 0.84
- 振 幅 7.98%
- 历史最低 0.50
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多B of A Securities Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $8
B of A Securities analyst Tazeen Ahmad initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $8.
07-11 20:20
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock
Taysha Gene Therapies (NASDAQ:TSHA) underwent analysis by 10 analysts in the la...
07-01 20:04
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted stock options to purchase 401,000 shares to two new employees under its 2023 Inducement Plan. The options have an exercise price of $2.785, a 10-year term, and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years, contingent on continued employment. The company focuses on developing AAV-based gene therapies for severe monogenic CNS diseases, ...
06-06 12:00
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Taysha Gene Therapies announced updates on its TSHA-102 program for Rett syndrome, highlighting clinical trial data, caregiver insights, and biodistribution studies of its AAV9 gene therapy. The findings demonstrate potential to improve developmental milestones and align with FDA goals, offering hope for patients and families affected by this rare disorder.
06-03 21:17
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
Where Taysha Gene Therapies Stands With Analysts
Taysha Gene Therapies (NASDAQ:TSHA) underwent analysis by 7 analysts in the las...
06-03 03:00
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Taysha Gene Therapies Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the
05-29 04:03
